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The therapeutic goal in acromegaly is to reduce morbidity and mortality by removing tumour mass and restoring GH and IGF-I levels to the normal range. According to Giustina et al., 2 the biochemical control of acromegalic disease is achieved if:
• random GH is <0.4µg/l or mean integrated 24-hour GH is <2.5µg/l;
• GH nadir is <1.0µg/l after a 75g oral glucose tolerance test (OGTT); and
• IGF-I is in the normal range adjusted for age and sex.
Currently available treatments for acromegaly include neurosurgery, radiotherapy and medical therapy with dopamine agonists, somatostatin analogues and the GH receptor antagonist pegvisomant.
The first-line therapeutic approach for acromegaly is still debated. Petrossians et al. 4 and Colao et al., 5 in two independent retrospective studies, showed that gross total tumour resection increases the probability of achieving and maintaining safe levels of GH and IGF-I by post-operative administration of somatostatin analogues. Radiotherapy, both conventional external-beam and stereotactic radiosurgery, is indicated for patients with recurrence or persistence of disease activity after unsuccessful surgery and in those who are resistant to or intolerant of medical treatment.
However, limitations of radiotherapy include the slow attenuation of GH and IGF-I levels, requiring five to 10 years to achieve maximal hormonal control, 6 and sometimes secondary damage to near cerebral tissue or hypopituitarism. Moreover, EF and early (E) to late or atrial (A) peak velocities ratio (E/A) were found to increase, whereas isovolumic relaxation time (IVRT) decreased after therapy with pegvisomant, indicating the enhancement of systolic and diastolic performance and the possibility of preventing the development or the progression of cardiac insufficiency.
Effect on Metabolic Complications
Impaired glucose tolerance (IGT) and overt diabetes, associated with hyperinsulinaemia and insulin resistance, are common in acromegalic patients, with an estimated prevalence of 19-56% for diabetes and 16-46% for IGT.
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Medical Consequences of Long-term Treatment of Acromegaly The incidence of hypercholesterolaemia in the acromegalic population is similar to that in the general population, whereas the incidence of type IV hypertriglyceridaemia is almost three times higher than in controls and occurs principally in acromegalic patients with a higher insulin response.
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Furthermore, GH
stimulates apolipoprotein E (Apo-E) and apolipoprotein A-I (Apo A-I) secretion. 40 Moreover, elevated levels of serum lipoprotein-α concentrations have been found in both active patients and those with controlled disease.
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Disease control improves glucose tolerance and diabetes.
Somatostatin analogues alter, albeit modestly, glucose tolerance and insulin resistance. Ronchi et al. 42 observed that after treatment with octreotide LAR, fasting glucose was increased and fasting insulin was decreased compared with baseline, but the homeostasis model assessment of insulin resistance (HOMA-IR) significantly decreased and became similar to that recorded in control subjects. We observed that the negative effect of somatostatin analogues on insulin levels seems to be more evident at the beginning of treatment, whereas glucose tolerance usually improves during longterm treatment with these drugs. 43, 44 We also found 45 that patients with normal glucose tolerance at the beginning of therapy did not develop impaired glucose tolerance after long-term treatment with high doses of octreotide LAR doses (up to 40mg every 28 days); therefore, it is more important to consider individual predisposition to diabetes than somatostatin analogue dose in the development of glucose intolerance during treatment with these drugs. The GH antagonist pegvisomant is effective in improving insulin sensitivity and glucose metabolism, inducing a significant decrease in fasting glucose to normal levels [46] [47] [48] A general improvement in lipid profile has been observed in patients treated with octreotide, although no impact on small and/or dense lowdensity lipoprotein (LDL) particles has been obtained. 49 In our series, lipid profile abnormalities were generally improved by treatment with somatostatin analogues. 50 The GH receptor antagonist has been found to increase total cholesterol levels and total/HDL-cholesterol ratio and to decrease serum lipoprotein-α concentrations.
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Effect on Respiratory Complications
In acromegaly, respiratory disorders (see Table 2 ) cause illness and impaired physical performance, contributing to 25% of all deaths recorded in this condition, where respiratory mortality appears to be at least three-fold higher than in normal subjects. 52 Whether acromegalic arthropathy can be reversed by controlling GH and IGF-I levels is still questioned. However, the biochemical control achieved by long-term treatment has been found to improve symptoms and signs of acromegalic arthropathy. 50 Octreotide has been demonstrated to induce a mild to moderate improvement in pain, crepitus and range of motion. Similarly, we have observed that after lanreotide 64 or octreotide LAR treatment, 65 Pituitary Disorders Medical Consequences of Long-term Treatment of Acromegaly
cartilage thickness measured by ultrasonography at the shoulder, wrist and left knee was significantly reduced, suggesting that the suppression of circulating serum GH and IGF-I levels is associated with a significant decrease in joint thickness and the improvement of carpal tunnel syndrome.
Effect on Neoplasia Development
Malignancies constitute the third cause of mortality in acromegaly.
The relative risk of cancer differs from that in the general population and is still debated. In the study by Orme et al., 66 no significant increase of cancer mortality was found in a cohort of 1,362 patients, suggesting that the incidence of cancer was lower than in the general population but the rate of death from colon cancer was higher than expected. Digestive tumours (particularly colon adenomatous polyps and tubular, villous or tubulo-villous adenomas) constitute the most frequent malignancies recorded in acromegaly, representing nearly 27% of all malignancies developing in acromegaly.
The mechanism responsible for the enhanced epithelial cell proliferation of sigmoid crypts seems to be related to IGF-I excess, 67, 68 whereas IGF-binding protein (IGFBP)-3 plays a pro-apoptotic and antiproliferative role, and its serum levels are negatively correlated with cancer risk, 69 displaying a possible mechanism compensating for these growth-promoting effects of IGF-I on colon mucosa. Other possible mechanisms are related to the decrease in the number of Blymphocytes and natural killers and the increase in T-lymphocytes in the colon mucosa, 70 and to bile acid secretion. 71 Hyperinsulinaemia has been described as a further possible mechanism associated with colon adenomas and carcinomas, especially in acromegalic patients with IGT or overt diabetes. 72 Disease activity, GH and IGF-I levels, disease duration and a family history of colon cancer are related to colon adenomas, but do not predict their occurrence. 73 Thyroid cancers constitute 3.1% of neplasms in acromegaly: thyroid tumours are predominantly papillary and occasionally aggressive, rarely occurring multifocal tumours, 74 with a low mortality rate.
No increase in breast or lung cancer incidence has been previously reported in acromegaly. 75 On the other hand, acromegaly predisposes to benign prostate hypertrophy, occurring in 80% of active patients and in 30% of cured acromegalic patients. 76 Only limited data are available about the impact of long-term treatment of acromegaly on malignancies. However, a decrease of GH, IGF-I and IGFBP-3 levels has been reported to induce the reduction of prostate volume in patients achieving disease control only if their age was less than 50 years, 77 indicating that chronic elevation of GH and IGF-I levels constitutes a proliferative stimulus for prostatic stromal cells independent of androgen status. Pituitary Disorders 
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